Concert Pharma gets $8 million in milestone after Phase I trial for drug to treat inflammatory diseases and cancer

8 October 2015

Concert Pharmaceuticals (Nasdaq: CNCE) on Thursday said it has received $8 million in milestone payments from US biotech company Celgene Corp (Nasdaq: CELG) following the completion of early stage trial of the drug candidate to treat for inflammatory diseases and cancer.

Roger Tung, chief executive of Concert Pharmaceuticals, said: ““We are encouraged by the favorable pharmacokinetic profile of CTP-730 observed in our Phase I clinical trials. We believe that selective incorporation of deuterium in apremilast has resulted in a potential next generation anti-inflammatory agent.”

The Phase I program included both single and multiple ascending dose trials. The Phase I clinical trials assessed the safety, tolerability and pharmacokinetics of CTP-730 in 85 healthy subjects. Treatment with CTP-730 was generally well tolerated and no serious adverse events were observed. The most common adverse events were similar to those already identified for apremilast.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK